Overview
GENSCRIPT BIO (1548)
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in the United S...
- Open
- 30.380
- High
- 30.680
- Low
- 28.320
- Prev. Close
- 30.380
- Volume
- 37.34M
- Turnover
- 1.11B
- Avg Price
- 29.637
- Bid/Ask Ratio
- -43.86%
- Amplitude
- 7.77%
- 52wk High
- 49.460
- Volume Ratio
- 1.29
- Turnover Ratio
- 1.63%
- 52wk Low
- 10.360
- HK Mkt Cap
- 69.62B
- Market CapHKD
- 69.62B
- P/ETTM
- Loss
- P/EDynamic
- Loss
- P/EStatic
- --
- EPSTTM
- -2.19
- EPSDynamic
- -0.888
- EPSStatic
- --
- BVPS
- 13.35
- P/B
- 2.28
- HK Shares
- 2.28B
- Dividend YieldTTM
- --
- DividendTTM
- --
- Shares
- 2.28B
- Min lot size
- 1,000
- Currency
- HKD
GENSCRIPT BIO Analyst Rating
View moreForecast & Rating
Nov 2, 2026- Strong buy71.43%
- Buy28.57%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
- Strong buy
- 5
- Buy
- 2
- Hold
- 0
- Sell
- 0
- Strong sell
- 0
Daily Events
- Nov, 16
GenScript Biotech experienced a volatile session today, declining over 6% to HK$28.40 in the morning before staging a strong afternoon rebound, closing up 0.33% at HK$30.48. The morning selloff was driven by Q2 results—net loss jumped 407% year-over-year to HK$507 million, while revenue fell 22% to HK$1.59 billion. However, afternoon gains found support from new catalysts: JPMorgan noted the US nucleic acid screening rules are manageable, and Morgan Stanley highlighted accelerating China AI drug R&D financing that will boost wet lab demand, positioning the company as a beneficiary in the biotech outsourcing sector. GenScript is up 138% year-to-date but has pulled back 38% from its October high of HK$49.46, currently trading below its 20-day and 60-day moving averages, though the consensus analyst target remains above the current price, reflecting longer-term confidence in its AI and R&D outsourcing prospects.
- Nov, 13
GenScript Biotech fell 4.58% to 30.38 HKD today, as the technical MACD death cross extended the pullback momentum. Q2 revenue of 15.85 billion HKD held sequentially flat but declined 22.15% year-over-year, while consecutive quarterly losses reached 5.07 billion HKD with a net margin of -31.99%. From a price standpoint, the stock has retreated 38.58% from its October peak of 49.46 HKD, yet remains up 137.53% year-to-date; currently trading well below both its 20-day moving average of 33.29 HKD and 60-day average of 36.06 HKD, signaling technical pressure. JPMorgan considers new nucleic acid screening regulations a manageable issue, while Morgan Stanley highlights that accelerating AI drug R&D financing in China should support wet lab service demand, providing some potential foundation for recovery.
- Nov, 12
GenScript Biotech fell 6% to close at HK$31.84, pressured by a combination of broader Hong Kong market weakness (Hang Seng Index down 0.92%) and company-specific headwinds. The stock opened at HK$33.50 but retreated steadily through the morning session, peaking at HK$33.38 before surrendering those gains in the afternoon. The pullback caps a volatile week—the weekly recap noted a 15.04% decline—and reflects profit-taking from the stock's robust 148.94% year-to-date surge from HK$12.79. Adding to near-term uncertainty, JPMorgan flagged that new U.S. nucleic acid screening regulations pose operational challenges, though the bank characterized them as 'manageable.' Fundamentally, the company faces significant profitability headwinds: Q2 2026 delivered a net loss of HK$507.2 million on HK$1.59 billion in revenue (down 22% year-over-year), compounded by a deeply negative 31.99% net margin. Technically, the stock has slipped below both the 20-day moving average (HK$33.35) and 60-day moving average (HK$36.04), signaling momentum loss and now trading 35.62% below its October 5 high of HK$49.46. Morgan Stanley's recent positive commentary on China's AI drug R&D financing momentum offers a potential longer-term offset to near-term operating challenges.
- Nov, 11
GenScript Biotech experienced significant intraday volatility, declining to an intraday low of HK$31.38 in the morning session before recovering to close at HK$34.74, up 2.72% from the previous close of HK$33.82, suggesting underlying support at lower levels. The stock has surged 171.62% year-to-date but remains 29.76% below its 52-week high of HK$49.46; the latest two quarters showed operating revenues declining 22.15% and 21.48% year-over-year, with Q2 net loss reaching HK$507 million. However, Morgan Stanley highlighted accelerating AI drug R&D financing in China driving demand for the company's wet lab services, while Huatai raised earnings forecasts and reiterated a buy rating, signaling analyst confidence in its AI-assisted drug discovery platform. The stock currently trades between its 20-day average (HK$33.50) and 60-day average (HK$36.00).
- Nov, 10
GenScript Biotech surged approximately 8% to HK$33.82 today, reaching an intraday high of HK$34.94 in the morning session before retracing in afternoon trading. The gains are primarily supported by favorable industry tailwinds: Morgan Stanley notes that accelerating AI drug R&D financing in China should drive 'wet lab' demand growth, Huatai upgraded earnings forecasts with a reiterated buy rating, while JP Morgan assessed new nucleic acid screening rules as manageable. However, fundamental headwinds persist: revenues declined over 22% year-over-year in recent quarters, Q2 recorded a net loss of HK$507 million, and net profit margins remain deeply negative at -32%. Regarding valuation, the stock has surged 164% year-to-date but trades 31% below its 52-week high of HK$49.46 reached in early October, currently positioned between its 20-day and 60-day moving averages with a market capitalization of approximately HK$77.2 billion.
